Today marks an important point in our journey to patients as HotSpot Therapeutics announces its $100MM Series C financing. This infusion of…
Read more
Now 10 years into the golden era of immuno-oncology (I-O) following the first FDA approval of ipilimumab (anti-CTLA4) in 2011…
Read more
Returning to work following the pandemic presents an opportunity to think creatively about how to re-configure the workplace
Read more